Terms: = Leukemia AND CARS, P49589, 833, ENSG00000110619 AND Treatment
204 results:
1. How to Test Human CAR T Cells in Solid Tumors, the Next Frontier of CAR T Cell Therapy.
Cochrane RW; Fiorentino A; Allen E; Robino RA; Quiroga J; Ferreira LMR
Methods Mol Biol; 2024; 2748():243-265. PubMed ID: 38070118
[TBL] [Abstract] [Full Text] [Related]
2. CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors.
Dragon AC; Beermann LM; Umland M; Bonifacius A; Malinconico C; Ruhl L; Kehler P; Gellert J; Weiß L; Mayer-Hain S; Zimmermann K; Riese S; Thol F; Beutel G; Maecker-Kolhoff B; Yamamoto F; Blasczyk R; Schambach A; Hust M; Hudecek M; Eiz-Vesper B
Front Immunol; 2023; 14():1219165. PubMed ID: 37915564
[TBL] [Abstract] [Full Text] [Related]
3. Chimeric Antigen Receptor T Cells: Immunotherapy for the treatment of leukemia, Lymphoma, and Myeloma.
Rodríguez Gil de Montes AL; Spencer LM
Mol Cancer Ther; 2023 Nov; 22(11):1261-1269. PubMed ID: 37596239
[TBL] [Abstract] [Full Text] [Related]
4. Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Shown in Several Preclinical Models.
Yang M; Guan T; Chen CF; He LF; Wu HM; Zhang RD; Li Y; Lin YC; Zeng H; Wu JD
J Immunother; 2023 Oct; 46(8):285-294. PubMed ID: 37584622
[TBL] [Abstract] [Full Text] [Related]
5. Novel chimeric antigen receptor targets and constructs for acute lymphoblastic leukemia: Moving beyond CD19.
Acharya L; Garg A; Rai M; Kshetri R; Grewal US; Dhakal P
J Investig Med; 2024 Jan; 72(1):32-46. PubMed ID: 37497999
[TBL] [Abstract] [Full Text] [Related]
6. Chimeric antigen receptor T cells for acute myeloid leukemia.
Fetsch V; Zeiser R
Eur J Haematol; 2024 Jan; 112(1):28-35. PubMed ID: 37455578
[TBL] [Abstract] [Full Text] [Related]
7. c-Met is a chimeric antigen receptor T-cell target for treating recurrent nasopharyngeal carcinoma.
Huo Q; Lv J; Zhang J; Huang H; Hu H; Zhao Y; Zhang X; Wang Y; Zhou Y; Qiu J; Ye Y; Huang A; Chen Y; Qin L; Qin D; Li P; Cai G
Cytotherapy; 2023 Oct; 25(10):1037-1047. PubMed ID: 37436338
[TBL] [Abstract] [Full Text] [Related]
8. Rapid generation of CD19 CAR-T cells by minicircle DNA enables anti-tumor activity and prevents fatal CAR-B leukemia.
Ye X; Wu Y; Zhang H; Shi L; Zhou Y; Guo S; Dong J; Cai J
Cancer Lett; 2023 Aug; 568():216278. PubMed ID: 37354981
[TBL] [Abstract] [Full Text] [Related]
9. Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche.
Alberti G; Arsuffi C; Pievani A; Salerno D; Mantegazza F; Dazzi F; Biondi A; Tettamanti S; Serafini M
Front Immunol; 2023; 14():1192333. PubMed ID: 37304257
[TBL] [Abstract] [Full Text] [Related]
10. T cells with split cars specific for NKG2D ligands and PD-L1 exhibit improved selectivity towards monocyte-derived cells while effective in eliminating acute myeloid leukaemia in vivo.
Sun L; Jiang G; Ng YY; Xiao L; Du Z; Wang S; Zhu J
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10189-10201. PubMed ID: 37270461
[TBL] [Abstract] [Full Text] [Related]
11. Co-opting signalling molecules enables logic-gated control of CAR T cells.
Tousley AM; Rotiroti MC; Labanieh L; Rysavy LW; Kim WJ; Lareau C; Sotillo E; Weber EW; Rietberg SP; Dalton GN; Yin Y; Klysz D; Xu P; de la Serna EL; Dunn AR; Satpathy AT; Mackall CL; Majzner RG
Nature; 2023 Mar; 615(7952):507-516. PubMed ID: 36890224
[TBL] [Abstract] [Full Text] [Related]
12. Chimeric Antigen Receptor T-cell Therapy in Cancer: A Critical Review.
Sharma R; Suravarjhula L; Banerjee M; Kumar G; Kumar N
Curr Drug Res Rev; 2023; 15(3):241-261. PubMed ID: 36825696
[TBL] [Abstract] [Full Text] [Related]
13. CAR-T Cell Therapy: the Efficacy and Toxicity Balance.
Chohan KL; Siegler EL; Kenderian SS
Curr Hematol Malig Rep; 2023 Apr; 18(2):9-18. PubMed ID: 36763238
[TBL] [Abstract] [Full Text] [Related]
14. The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial.
Xuan L; Dai M; Jiang E; Wang Y; Huang F; Fan Z; Xu N; Nie D; Liang X; Chen H; Ye J; Shi P; Liu H; Jin H; Lin R; Yan C; Zhang Y; Sun J; Han M; Liu Q
Lancet Haematol; 2023 Mar; 10(3):e178-e190. PubMed ID: 36702138
[TBL] [Abstract] [Full Text] [Related]
15. CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses.
Bove C; Arcangeli S; Falcone L; Camisa B; El Khoury R; Greco B; De Lucia A; Bergamini A; Bondanza A; Ciceri F; Bonini C; Casucci M
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36593069
[TBL] [Abstract] [Full Text] [Related]
16. CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19.
Vanegas YM; Mohty R; Gadd ME; Luo Y; Aljurf M; Qin H; Kharfan-Dabaja MA
Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):81-93. PubMed ID: 36537906
[TBL] [Abstract] [Full Text] [Related]
17. Clinical Applications of Flow Cytometry in Cancer Immunotherapies: From Diagnosis to treatments.
Mishra HK
Methods Mol Biol; 2023; 2593():93-112. PubMed ID: 36513926
[TBL] [Abstract] [Full Text] [Related]
18. Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (cars).
Cassioli C; Patrussi L; Valitutti S; Baldari CT
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430728
[TBL] [Abstract] [Full Text] [Related]
19. Next generations of CAR-T cells - new therapeutic opportunities in hematology?
Tomasik J; Jasiński M; Basak GW
Front Immunol; 2022; 13():1034707. PubMed ID: 36389658
[TBL] [Abstract] [Full Text] [Related]
20. Co-Stimulatory Receptor Signaling in CAR-T Cells.
Honikel MM; Olejniczak SH
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139142
[TBL] [Abstract] [Full Text] [Related]
[Next]
